BPC-157 (5 mg Vial) Dosage Protocol
A 15-amino-acid synthetic peptide derived from a gastric protein sequence, studied for tissue-healing and cytoprotective properties in preclinical models.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
The following educational protocol uses a 3.0 mL bacteriostatic water reconstitution to create a 1.67 mg/mL concentration — chosen to make syringe units readable above 10 units per injection for accuracy.
Standard / Gradual Approach (3 mL = 1.67 mg/mL)
Route: Subcutaneous | Frequency: Once daily
| Week | Daily Dose | U-100 Syringe Units | Volume (mL) |
|---|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 12 units | 0.12 mL |
| Weeks 3–4 | 400 mcg (0.4 mg) | 24 units | 0.24 mL |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 36 units | 0.36 mL |
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water into a sterile insulin syringe.
- Inject slowly down the inside glass wall of the peptide vial — avoid directing the stream onto the powder.
- Gently swirl or roll the vial until fully dissolved. Do not shake.
- Label with the reconstitution date. Refrigerate immediately at 2–8°C (35.6–46.4°F), protected from light.
Supplies Planning
Estimated supply needs for an 8–16 week daily protocol at the gradual titration schedule.
| Item | 8 Weeks | 12 Weeks | 16 Weeks |
|---|---|---|---|
| BPC-157 vials (5 mg each) | 6 vials | 9 vials | 12 vials |
| Insulin syringes (U-100) | 56 | 84 | 112 |
| Bacteriostatic water (10 mL bottles) | 2 × 10 mL | 3 × 10 mL | 4 × 10 mL |
| Alcohol swabs | 2 × 100-pack | 2 × 100-pack | 3 × 100-pack |
How BPC-157 Works
BPC-157 (Body Protection Compound-157) is a synthetic peptide corresponding to a partial sequence of human gastric juice protein. It consists of 15 amino acids and was originally identified through research on the gastroprotective properties of gastric mucosa.
Preclinical studies suggest BPC-157 modulates nitric oxide (NO) pathways and growth-factor expression — particularly the upregulation of VEGF and EGF receptor expression — to promote angiogenesis and collagen deposition in damaged tissues. Animal models have reported accelerated healing of gut epithelium, tendons, ligaments, and skeletal muscle injuries.
A Phase I oral safety trial (ClinicalTrials.gov NCT02637284) has been completed. A small human case series reported improvements following intra-articular administration. However, large-scale, controlled human efficacy data are not yet available, and all dosing parameters applied in research contexts are extrapolated from preclinical models.
Preclinical Findings & Side Effect Profile
- Supports tissue repair in gut, tendon, muscle, and skin injury models in multiple rodent studies.
- Demonstrates anti-inflammatory and cytoprotective properties through NO-system modulation.
- Phase I safety study reported good tolerability with no serious adverse events at tested oral doses.
- Occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.
- No lethal dose has been established in animal models up to approximately 20 mg/kg.
- Long-term human safety and efficacy remain under investigation.
Storage Instructions
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilized (dry) | −20°C (−4°F) | Up to 24 months | Dry, dark conditions; minimize moisture |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days | Avoid freeze-thaw cycles; light-protected |
Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
All injection guidance is adapted from WHO and CDC clinical best-practice guidelines for subcutaneous administration:
- Clean the vial rubber stopper and skin injection site with an alcohol swab; allow both to dry fully before proceeding.
- Pinch a skin fold. Insert the needle at 45–90° into subcutaneous tissue (abdomen, thigh, or upper arm).
- Aspiration is not necessary for subcutaneous injections; inject slowly and steadily.
- Rotate injection sites systematically to avoid lipohypertrophy.
- Use one new sterile syringe per injection; dispose in a sharps container per WHO guidelines.
- Inject slowly; wait 2–3 seconds before withdrawing the needle to ensure full dose delivery.